COMMUNIQUÉS West-GlobeNewswire

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
10/04/2024
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster [...]
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
10/04/2024
450-Bed Hospital Purchases BVA-100 ™ Blood Volume Analyzer to Launch H eart Failure P rogram Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume [...]
Elucent Medical Secures Series C Funding to Advance Oncologic Surgery Innovation
10/04/2024
EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical technology company transforming the field of surgical navigation through In-Site Spatial Intelligence (iSI) is pleased to [...]
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10/04/2024
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management [...]
Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
10/04/2024
Excision to give three oral presentations and outline new data in three posters from preclinical programs for herpes keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV) as well as a next-generation AAV vector Update [...]
Arcutis Appoints David Topper as Chief Financial Officer
10/04/2024
Industry veteran with over 40 years of experience in finance, investment management, and investment banking WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a [...]
Skye Bioscience Uplists to The Nasdaq Global Market
10/04/2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel [...]
SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures
10/04/2024
First-ever telesurgery using SSi Mantra performed on an animal in India FORT LAUDERDALE, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a [...]
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
10/04/2024
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer [...]
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
10/04/2024
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
10/04/2024
Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the [...]
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
10/04/2024
With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwide Enibarcimab has [...]
Nusano to Present at Jefferies Radiopharma Innovation Summit
10/04/2024
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit [...]
Recce Pharmaceuticals Provides Business Update
10/04/2024
Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeks Expansion of Phase I/ [...]
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
10/04/2024
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering [...]
Kura Oncology to Participate in Stifel Targeted Oncology Forum
10/04/2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/04/2024
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today [...]
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10/04/2024
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity [...]
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
10/04/2024
Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA 1 FY2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the [...]

Pages